logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Isoniazid preventive therapy in human immunodeficiency virus-infected persons : Long-term effect on development of tuberculosis and survival.

    Article - En anglais

    Background 

    Although the short-term benefit of isoniazid prophylaxis in patients coinfected with human immunodeficiency virus (HIV) and tuberculosis has been shown, long-term benefits are unknown.

    Methods 

    Historical cohort study in an acquired immunodeficiency syndrome unit at a tertiary referral hospital.

    A sample of 121 HIV-infected patients with positive results on a purified protein derivative test were followed up for development of active tuberculosis and survival.

    Patients who received isoniazid prophylaxis were compared with patients who did not receive prophylaxis.

    Results 

    Of the 121 patients examined, 29 (24%) completed a 9-to 12-month course of isoniazid prophylaxis (median follow-up, 89 months), and 92 (76%) did not receive the drug (median follow-up, 60 months).

    Active tuberculosis developed in 46 patients (38%). The incidence of tuberculosis was higher among patients with no prophylaxis (9.4 per 100 patient-years) than among patients with isoniazid prophylaxis (1.6 per 100 patient-years) (P=006).

    Risk for development of tuberculosis was associated with the absence of isoniazid prophylaxis (relative risk [RR], 6.55 ; 95% confidence interval [CI], 2.02-21.19).

    Death during the period of study was more frequent in patients who did not receive isoniazid (50/92 or 54%) than in patients who received isoniazid (7/29 or 24%) (P=008). (...)

    Mots-clés Pascal : SIDA, Virose, Infection, Virus immunodéficience humaine, Lentivirinae, Retroviridae, Virus, Association, Tuberculose, Mycobactériose, Bactériose, Etude cohorte, Prévention, Isoniazide, Evaluation, Long terme, Mycobacterium tuberculosis, Mycobacteriaceae, Mycobacteriales, Actinomycetes, Bactérie, Survie, Homme, Immunopathologie, Immunodéficit, Organisation santé, Antituberculeux

    Mots-clés Pascal anglais : AIDS, Viral disease, Infection, Human immunodeficiency virus, Lentivirinae, Retroviridae, Virus, Association, Tuberculosis, Mycobacterial infection, Bacteriosis, Cohort study, Prevention, Isoniazid, Evaluation, Long term, Mycobacterium tuberculosis, Mycobacteriaceae, Mycobacteriales, Actinomycetes, Bacteria, Survival, Human, Immunopathology, Immune deficiency, Public health organization, Antituberculous agent

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0429068

    Code Inist : 002B02S07. Création : 19/12/1997.